Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW014 in healthy subjects and type 2 diabetes mellitus patients
NCT05579314Phase 1Completed
- Sponsor
- Sciwind Biosciences
- Start
- Sep 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XW014 in type 2 diabetes mellitus (T2DM) (8 cohorts), sponsored by Sciwind Biosciences. Primary endpoints: Treatment Emergent Adverse Events at 11 weeks, Serious Adverse Events at 11 weeks and 4 more. Started Sep 2022; status: completed.
02
Drugs
XW014
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05579314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579314.